sub:assertion {
  d:DB00008 v:identifier "DB00008" ;
    v:namespace "drugbank" ;
    v:uri "http://bio2rdf.org/drugbank:DB00008" ;
    v:x-identifiers.org <http://identifiers.org/drugbank/DB00008> ;
    dv:drugbank-id "BIOD00043" , "BTD00043" , "DB00008" ;
    dv:x-ahfs <http://bio2rdf.org/ahfs:08:18.20> ;
    dv:x-atc <http://bio2rdf.org/atc:L03AB11> ;
    dv:x-cas <http://bio2rdf.org/cas:198153-51-4> ;
    dv:x-dpd <http://bio2rdf.org/dpd:2248077> ;
    dv:x-genbank <http://bio2rdf.org/genbank:J00207> ;
    dv:x-pharmgkb <http://bio2rdf.org/pharmgkb:PA164749390> ;
    dv:x-uniprot <http://bio2rdf.org/uniprot:P01563> ;
    dv:x-wikipedia <http://bio2rdf.org/wikipedia:Peginterferon_alfa-2a> ;
    dct:description "Human interferon 2a, is a covalent conjugate of recombinant alfa-2a interferon with a single branched bis-monomethoxy polyethylene glycol (PEG) chain. The PEG moiety is linked at a single site to the interferon alfa moiety via a stable amide bond to lysine. Peginterferon alfa-2a has an approximate molecular weight of 60,000 daltons. Interferon alfa-2a is produced using recombinant DNA technology in which a cloned human leukocyte interferon gene is inserted into and expressed in Escherichia coli. The resultant protein is 165 amino acids. The PEG strand protects the molecule in vivo from proteolytic breakdown, substantially increases its in vivo half-life, and reduces immunogenicity by wrapping around and physically hindering access to the protein portion of the molecule."@en ;
    dct:identifier "drugbank:DB00008" ;
    dct:title "Peginterferon alfa-2a"@en ;
    a dv:Drug ;
    rdfs:label "Peginterferon alfa-2a [drugbank:DB00008]"@en ;
    rdfs:seeAlso <http://www.drugbank.ca/drugs/DB00008> , <http://www.drugs.com/cdi/peginterferon-alfa-2a.html> , <http://www.rxlist.com/cgi/generic3/pegasys.htm> .
}